glp-1 obesity drug news today october 2025 oct 21 New Pill Foundayo (Orforglipron) Gets FDA Approval for GLP-1 Agonists: Using Semaglutide, Tirzepatide, – GLP-1 Injection Sites: Where Size:120 BLOG

glp-1 obesity drug news today october 2025 oct 21 New Pill Foundayo (Orforglipron) Gets FDA Approval for GLP-1 Agonists: Using Semaglutide, Tirzepatide, – GLP-1 Injection Sites: Where Size:120 BLOG

GLP-1 Injection Sites: Where to Inject and Why

She highlighted key mechanisms of GLP-1 therapy, which include increased glucose-dependent insulin secretion, decreased inappropriate glucagon secretion, slowed gastric emptying, and reduced food intake—ultimately leading to weight loss

BLOG

Size:120

The results showed that in high risk patients with T2D liraglutide reduced the risk of MACE by 13% (primary endpoint included cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke) ( In the ELIXA and the EXSCEL trials, GLP-1RAs (once daily lixisenatide and once weekly exenatide, respectively) didn’t provide benefit in MACE reduction compared to placebo, but were non-inferior to placebo for the primary composite outcome of MACE